Wei Y. Jen

Hematology
1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Journal: Cancer
Published: March 30, 2026

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission.

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission.

Journal: Haematologica
Published: March 23, 2026

Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.

Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.

Journal: Haematologica
Published: March 10, 2026

Acute leukemia with BCL11B rearrangements: Genetic landscape, BCL11B expression, and therapeutic response.

Acute leukemia with BCL11B rearrangements: Genetic landscape, BCL11B expression, and therapeutic response.

Journal: Human pathology
Published: December 17, 2025

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Journal: Blood cancer journal
Published: December 04, 2025

Case Report: FIA plus venetoclax in a patient on hemodialysis.

Case Report: FIA plus venetoclax in a patient on hemodialysis.

Journal: Frontiers in oncology
Published: November 05, 2025

Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.

Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.

Journal: Leukemia
Published: May 28, 2025

PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes.

PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes.

Journal: Haematologica
Published: March 19, 2025

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine.

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine.

Journal: Cancers
Published: June 28, 2022

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia.

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia.

Journal: Blood advances
Published: April 25, 2022
Showing 1-12 of 14

Last Updated: 09/26/2026